精品国产一区二区桃色

Journal News

Receptor antagonist reduces age-related bone loss in mice

Emily Ulrich
Aug. 6, 2025

Bone remodeling involves a regulation between osteoblasts for bone formation and osteoclasts for bone resorption, and this process shifts out of balance with age and with the development of osteoporosis. The complement system, activated as part of the innate immune response to infection, also functions in bone development. The G protein-coupled receptor C3aR is expressed as a component of the complement system in bone marrow cells. Fangyu Li and Shun Cui at Huazhong University of Science and Technology investigated whether C3aR plays a role in age-related impacts on bone remodeling. They published their recent in the Journal of Biological Chemistry.

3D rendering of the three stages of osteoporosis featuring progressive bone loss.
3D rendering of the three stages of osteoporosis featuring progressive bone loss.

The researchers first noted that C3aR expression trends upward as mice age, in conjunction with higher levels of senescence markers. In contrast, mice with C3aR knocked out showed an increase in bone mass compared to a control group of the same age. The C3aR knockout mice also exhibited higher expression of the osteogenic marker osteoprotegerin and lower expression of the osteoclast marker tartaric acid resistance phosphatase, suggesting a shift toward bone formation over resorption.

In addition, the authors tested a C3aR antagonist, called JR14a, in cells treated with D-galactose to mimic cell damage caused by aging  and found that the antagonist restored cell viability. They applied JR14a to a mouse model, and their histologic staining showed an increase in osteoblasts and a decrease in osteoclasts, suggesting partial inhibition of bone loss.

Fluorescence labeling experiments performed in this study indicated that JR14a initiates YAP1/β-catenin signaling, a pathway known to promote osteoblast differentiation. Future studies will help determine the details of downstream effects caused by C3aR inhibition and the possibility of targeting C3aR for relieving age-related dysfunction in bone remodeling.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Emily Ulrich

Emily Ulrich is the ASBMB’s science editor.

Get the latest from ASBMB Today

Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.

Pathogen-derived enzyme engineered for antibiotic design
Journal News

Pathogen-derived enzyme engineered for antibiotic design

Aug. 6, 2025

Engineered variants of a bacterial enzyme developed at the University at Buffalo accept larger substrates, paving the way for new acinetobactin-based antimicrobials. Read more about this recent JBC paper.

Omega-3 fats linked to healthy aging and improved heart metabolism
Journal News

Omega-3 fats linked to healthy aging and improved heart metabolism

Aug. 1, 2025

Scientists from the University of Iowa find that a diet high in polyunsaturated fatty acids from fish oil increases cardiac triglyceride uptake and improves insulin sensitivity. Read more about this recent JLR study.

RA patient blood reveals joint innerworkings
Journal News

RA patient blood reveals joint innerworkings

July 25, 2025

Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Feature

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.